Leveraging disease progression modeling to aid clinical decision and optimize drug development for Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary fibrosis: miscellaneous

Chair(s): Esther Jeritza Nossent, Laura Fabbri

Session type: Poster session

Tu Mai

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Survival in interstitial lung diseases 11 years observation of 2497 patients.

Magdalena Martusewicz-boros

Poster

Abstract

Association between smoking and prognosis in patients with idiopathic pulmonary fibrosis

Min Jee Kim

Poster

Abstract

Association between parenchymal B-cell follicles and CT-proven enlarged mediastinal lymph nodes in patients with pulmonary fibrosis

Sissel Kronborg-white

Poster

Abstract

A Retrospective Observational Study of post-COVID-19 patients - clinical outcome, follow-up and patient characteristics in Post-COVID Pulmonary Fibrosis (PC-PF)

Catherine Salisbury

Poster

Abstract

Interstitial lung disease increases the risk of severe COVID-19 infection; a retrospective registry-based epidemiological study of the entire adult Swedish population

Emil Ekbom

Poster

Abstract

Idiopathic pulmonary fibrosis mortality among ever-employed persons aged ?15 years, by industry and occupationUnited States, 2021

Jacek Mazurek

Poster

Abstract

Multidisciplinary management of interstitial lung disease in NHS Scotland

Emily Turner

Poster

Abstract

Surgical pulmonary biopsy in ILD: analysis of complications and survival

Sonia Pascual Garcia

Poster

Abstract

The prognostic value of blood eosinophils?monocyte count and Neutrophils/Lymphocyte ratio (NLR) in patients with IPF, CPFE and COPD?A retrospective multicenter cohort study

Yen-fu Chen

Poster

Abstract

Virtual pulmonary rehabilitation for people with idiopathic pulmonary fibrosis: a mixed methods feasibility study

Orlagh O'shea

Poster

Abstract

Evaluation of a German R-Scale questionnaire in various ILD diagnoses

Sina Stoltefuss

Poster

Abstract

FVC and DLCO evolution after initiation of antifibrotics as prognostic factors in IPF

Marie Vermant

Poster

Abstract

Second-line antifibrotics in patients with idiopathic pulmonary fibrosis: a real-life experience

Stefano Levra

Poster

Abstract

Leveraging disease progression modeling to aid clinical decision and optimize drug development for Idiopathic Pulmonary Fibrosis (IPF)

Tu Mai

Poster

Abstract

Correlation of traction bronchiectasis with lung function decline in patients with interstitial lung diseases

Tomonori Makiguchi

Poster

Abstract

IS THE PORTABLE CONCENTRATOR THE BEST SOLUTION TO CORRECT EXERCISE OXYGEN DESATURATION?

Ariadna Farre Maduell

Poster

Abstract

Physical activity measurement with questionnaire in idiopathic pulmonary fibrosis

Patrick Hurley

Poster

Abstract

Sulforaphane (SFN) derivatives attenuate at pulmonary fibrosis both in vivo bleomycin (BLM)-induced model and in vitro TGF-?1-induced model

Sung Hwan Jeong

Poster

Abstract

Occurrence of Pneumothorax in patients with pulmonary idiopathic fibrosis and acute respiratory failure treated with High-Flow Nasal Cannula: A Case Series

Chiara Di Maria

Abstract

The ERS International Congress 2023, Milan

#{title}